ADAPTIVE BIOTECHNOLOGIES(NASDAQ:ADPT) stock News

ADPT Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill

Adaptive Biotechnologies (NASDAQ:ADPT) Fits Minervini's Trend Template with Strong Growth Momentum

2 days ago - By: Zacks Investment Research - Mentions: CAH

Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?

4 days ago - By: The Motley Fool

Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

4 days ago - By: Yahoo Finance

Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

4 days ago - By: The Motley Fool

Adaptive (ADPT) Q2 Revenue Surges 36%

5 days ago - By: Zacks Investment Research

Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings

5 days ago - By: Zacks Investment Research - Mentions: ACAD

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

5 days ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

5 days ago - By: Benzinga - Mentions: AFG CXDO YUM PACK ...

Earnings Scheduled For August 5, 2025

9 days ago - By: Zacks Investment Research - Mentions: MRNA

Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates

19 days ago - By: Yahoo Finance

Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results

26 days ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

26 days ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

a month ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

a month ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

2 months ago - By: Yahoo Finance

Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy

2 months ago - By: Benzinga

Assessing Adaptive Biotechnologies: Insights From 5 Financial Analysts

2 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

2 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

2 months ago - By: Zacks Investment Research - Mentions: GSK AGEN SPRO

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

2 months ago - By: Zacks Investment Research - Mentions: MRNA AGEN

U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot

2 months ago - By: Zacks Investment Research - Mentions: HTZ SEZL

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

2 months ago - By: Yahoo Finance - Mentions: RIOT GIS NIO MRNA ...

Why Riot Platforms, Inc. (RIOT) Went Down On Wednesday

2 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

2 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

3 months ago - By: Zacks Investment Research - Mentions: CVS

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

3 months ago - By: Zacks Investment Research - Mentions: HTZ SEZL

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

3 months ago - By: Zacks Investment Research - Mentions: BMRN AGEN INZY

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

3 months ago - By: Zacks Investment Research - Mentions: ABBV AGEN

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer

3 months ago - By: Zacks Investment Research - Mentions: ALLO AGEN ELEV

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

3 months ago - By: Zacks Investment Research - Mentions: BEAM INSM ELEV

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

3 months ago - By: Zacks Investment Research

Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?

3 months ago - By: Zacks Investment Research - Mentions: SNY NVAX BEAM

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

3 months ago - By: Zacks Investment Research - Mentions: BEAM IOVA ELEV

ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock News

ADPT Latest News, Press Relases and Analysis

Adaptive Biotechnologies (NASDAQ:ADPT) Fits Minervini's Trend Template with Strong Growth Momentum

Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?

Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

Adaptive (ADPT) Q2 Revenue Surges 36%

Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Earnings Scheduled For August 5, 2025

Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy

Assessing Adaptive Biotechnologies: Insights From 5 Financial Analysts

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

Why Riot Platforms, Inc. (RIOT) Went Down On Wednesday

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut